vs
Side-by-side financial comparison of CAPITAL CITY BANK GROUP INC (CCBG) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $63.5M, roughly 1.5× CAPITAL CITY BANK GROUP INC). Vericel Corp runs the higher net margin — 25.0% vs 21.6%, a 3.4% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 6.0%). CAPITAL CITY BANK GROUP INC produced more free cash flow last quarter ($80.0M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 6.0%).
Texas Capital Bank is a bank headquartered in Dallas, Texas. The bank has branches located in every major city in Texas. Its parent bank holding company is Texas Capital Bancshares. It also operates an online-only banking division, Bask Bank.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
CCBG vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $63.5M | $92.9M |
| Net Profit | $13.7M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 29.3% | 24.1% |
| Net Margin | 21.6% | 25.0% |
| Revenue YoY | 6.0% | 23.3% |
| Net Profit YoY | 4.7% | 17.3% |
| EPS (diluted) | $0.80 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $63.5M | $92.9M | ||
| Q3 25 | $65.9M | $67.5M | ||
| Q2 25 | $63.2M | $63.2M | ||
| Q1 25 | $61.5M | $52.6M | ||
| Q4 24 | $59.9M | $75.4M | ||
| Q3 24 | $59.7M | $57.9M | ||
| Q2 24 | $58.9M | $52.7M | ||
| Q1 24 | $56.5M | $51.3M |
| Q4 25 | $13.7M | $23.2M | ||
| Q3 25 | $15.9M | $5.1M | ||
| Q2 25 | $15.0M | $-553.0K | ||
| Q1 25 | $16.9M | $-11.2M | ||
| Q4 24 | $13.1M | $19.8M | ||
| Q3 24 | $13.1M | $-901.0K | ||
| Q2 24 | $14.2M | $-4.7M | ||
| Q1 24 | $12.6M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 29.3% | 24.1% | ||
| Q3 25 | 32.0% | 5.1% | ||
| Q2 25 | 31.7% | -3.2% | ||
| Q1 25 | 35.8% | -24.3% | ||
| Q4 24 | 29.0% | 24.5% | ||
| Q3 24 | 26.1% | -4.3% | ||
| Q2 24 | 29.3% | -11.5% | ||
| Q1 24 | 27.2% | -10.7% |
| Q4 25 | 21.6% | 25.0% | ||
| Q3 25 | 24.2% | 7.5% | ||
| Q2 25 | 23.8% | -0.9% | ||
| Q1 25 | 27.4% | -21.4% | ||
| Q4 24 | 21.9% | 26.3% | ||
| Q3 24 | 22.0% | -1.6% | ||
| Q2 24 | 24.0% | -8.9% | ||
| Q1 24 | 22.2% | -7.5% |
| Q4 25 | $0.80 | $0.46 | ||
| Q3 25 | $0.93 | $0.10 | ||
| Q2 25 | $0.88 | $-0.01 | ||
| Q1 25 | $0.99 | $-0.23 | ||
| Q4 24 | $0.78 | $0.40 | ||
| Q3 24 | $0.77 | $-0.02 | ||
| Q2 24 | $0.83 | $-0.10 | ||
| Q1 24 | $0.74 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $552.9M | $354.6M |
| Total Assets | $4.4B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | $552.9M | $354.6M | ||
| Q3 25 | $540.6M | $321.9M | ||
| Q2 25 | $526.4M | $306.8M | ||
| Q1 25 | $512.6M | $295.5M | ||
| Q4 24 | $495.3M | $292.0M | ||
| Q3 24 | $476.5M | $257.5M | ||
| Q2 24 | $461.0M | $243.0M | ||
| Q1 24 | $448.3M | $233.9M |
| Q4 25 | $4.4B | $488.0M | ||
| Q3 25 | $4.3B | $453.3M | ||
| Q2 25 | $4.4B | $435.6M | ||
| Q1 25 | $4.5B | $424.6M | ||
| Q4 24 | $4.3B | $432.7M | ||
| Q3 24 | $4.2B | $390.4M | ||
| Q2 24 | $4.2B | $376.8M | ||
| Q1 24 | $4.3B | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $87.6M | $15.0M |
| Free Cash FlowOCF − Capex | $80.0M | $12.8M |
| FCF MarginFCF / Revenue | 126.1% | 13.8% |
| Capex IntensityCapex / Revenue | 12.0% | 2.4% |
| Cash ConversionOCF / Net Profit | 6.39× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $150.1M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $15.0M | ||
| Q3 25 | $21.6M | $22.1M | ||
| Q2 25 | $32.6M | $8.2M | ||
| Q1 25 | $21.9M | $6.6M | ||
| Q4 24 | $63.6M | $22.2M | ||
| Q3 24 | $12.8M | $10.2M | ||
| Q2 24 | $24.9M | $18.5M | ||
| Q1 24 | $14.6M | $7.2M |
| Q4 25 | $80.0M | $12.8M | ||
| Q3 25 | $19.8M | $19.5M | ||
| Q2 25 | $30.8M | $81.0K | ||
| Q1 25 | $19.5M | $-7.6M | ||
| Q4 24 | $54.9M | $8.5M | ||
| Q3 24 | $10.5M | $-9.2M | ||
| Q2 24 | $23.0M | $1.8M | ||
| Q1 24 | $12.4M | $-6.8M |
| Q4 25 | 126.1% | 13.8% | ||
| Q3 25 | 30.1% | 28.8% | ||
| Q2 25 | 48.7% | 0.1% | ||
| Q1 25 | 31.7% | -14.5% | ||
| Q4 24 | 91.7% | 11.2% | ||
| Q3 24 | 17.6% | -15.9% | ||
| Q2 24 | 39.0% | 3.4% | ||
| Q1 24 | 22.0% | -13.3% |
| Q4 25 | 12.0% | 2.4% | ||
| Q3 25 | 2.6% | 3.9% | ||
| Q2 25 | 2.9% | 12.9% | ||
| Q1 25 | 3.9% | 27.0% | ||
| Q4 24 | 14.5% | 18.3% | ||
| Q3 24 | 3.8% | 33.5% | ||
| Q2 24 | 3.3% | 31.8% | ||
| Q1 24 | 4.0% | 27.3% |
| Q4 25 | 6.39× | 0.65× | ||
| Q3 25 | 1.35× | 4.35× | ||
| Q2 25 | 2.17× | — | ||
| Q1 25 | 1.30× | — | ||
| Q4 24 | 4.86× | 1.12× | ||
| Q3 24 | 0.97× | — | ||
| Q2 24 | 1.76× | — | ||
| Q1 24 | 1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCBG
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
